COMP <GO>
BSX vs ABBV // FORWARD P/E MULTIPLE
Boston Scientific Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BSX 7
— ABBV 8
▲ FORWARD P/E MULTIPLE LEADER: BSX
LAST: $41.98 (-1.66%) • MKT CAP: $61.87B
forward-pe
18.5x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BSX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BSX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.00% | 70.20% | -1.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.20% | 29.00% | -19.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.8x | 33.3x | -17.50 | BSX | /valuation <GO> |
| Free Cash Flow Yield | 5.91% | 3.47% | +2.44 | BSX | /fcf-yield <GO> |
| Operating Margin | 18.00% | 24.60% | -6.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 14.00% | 6.90% | +7.10 | BSX | /net-margins <GO> |
| Revenue Growth (YoY) | 19.90% | 8.60% | +11.30 | BSX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.77 | 5.33 | -2.56 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | BSX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | BSX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.8 | 72.8 | -34.01 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.15 | -0.16 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 18.5x | 113.1x | -94.60 | BSX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $61.87B | $513.86B | -$451.99B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BSX REV | ABBV REV | BSX GROSS % | ABBV GROSS % | BSX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.07B | $61.16B | 69.0% | 70.2% | $3.66B | $17.82B |
| FY 2024 | $16.75B | $56.33B | 68.6% | 70.0% | $2.65B | $17.83B |
| FY 2023 | $14.24B | $54.32B | 44.0% | 44.0% | $1.86B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BSX // BETA 0.99
ABBV // BETA 1.15